Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

ESMO open·2026
Same author

TAMs and PD-1 networking in esophageal cancer: literature review.

ESMO gastrointestinal oncology·2026
Same author

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study.

ESMO real world data and digital oncology·2026
Same author

Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer.

ESMO gastrointestinal oncology·2026
Same author

Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same journal

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC).

Clinical genitourinary cancer·2026
Same journal

PROTEUS and the Perioperative Intensification Era in High-risk Prostate Cancer.

Clinical genitourinary cancer·2026
Same journal

Circulating Tumor DNA After Radical Cystectomy as a Marker of Minimal Residual Disease in Muscle-Invasive Bladder Cancer: A Literature Review.

Clinical genitourinary cancer·2026
Same journal

Trophoblastic-Differentiated Urothelial Carcinoma: Real-World Sequencing and Clinical Implications.

Clinical genitourinary cancer·2026
Same journal

Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.

Clinical genitourinary cancer·2026
Same journal

Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature.

Clinical genitourinary cancer·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The

M Liontos1, E Bournakis2, A Bournakis2

  • 1Department of Clinical Therapeutics, Alexandra Hospital National and Kapodistrian University of Athens, Athens, Greece.

Clinical Genitourinary Cancer
|August 27, 2024
PubMed
Summary
This summary is machine-generated.

Real-world data shows most metastatic castration-resistant prostate cancer (mCRPC) patients start with novel hormonal agents (NHAs). Sequencing to later lines often involves chemotherapy, indicating a need for optimized treatment strategies in mCRPC management.

Keywords:
GuidelinesNovel hormonal agentsProstatic neoplasmsTherapeutic strategymCRPC chemotherapy

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.6K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.6K

Related Experiment Videos

Last Updated: Jun 15, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.6K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.6K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Limited real-world data exists for managing metastatic castration-resistant prostate cancer (mCRPC) with novel therapies.
  • Understanding treatment patterns is crucial for optimizing patient care.

Purpose of the Study:

  • To analyze real-world management strategies for mCRPC patients initiating first-line (1L) therapy in Greece.
  • To describe therapeutic sequencing from 1L to second-line (2L) and third-line (3L) treatments.

Main Methods:

  • A retrospective, noninterventional study (PROSPECT) reviewed charts of 149 mCRPC patients.
  • Data was collected from 7 major Greek anticancer hospital clinics.
  • Descriptive analysis and Kaplan-Meier methods were used.

Main Results:

  • Most patients (78.5%) received novel hormonal agents (NHAs) in 1L, primarily enzalutamide and abiraterone.
  • In 2L, chemotherapy (docetaxel) was most common (72.1%).
  • Treatment sequencing from 1L to 2L predominantly involved NHA to chemotherapy (55.9%). Median treatment durations were 9.8 months (1L), 4.4 months (2L), and 3.7 months (3L).

Conclusions:

  • First-line NHA use aligns with guidelines for mCRPC.
  • Longer treatment duration with 1L NHAs suggests potential for improved 2L and 3L treatment optimization.
  • Further research is needed to refine sequential treatment recommendations for mCRPC.